Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi

Calando's management remains optimistic about deals in 2011. But some industry observers expect that it will take years of continued advancement in the RNAi field and a shift in its players' expectations before major deals are consummated.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.